Location: RPAH/Melanoma Institute Australia North Sydney
Trial status: Open
Treatment type: Radiotherapy
Stage: IA to IIC
Intent of treatment:Recurrence prevention

Title: RTN2: A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck

Location: Melanoma Institute Australia North Sydney/Westmead/ RPAH
Trial status: Open
Treatment type: Biomarker
Stage: IIIb/IIIc/IV
Intent of treatment:

Title: Biomarker evaluation of short-term administration of chemotherapeutic, immunological or biologic agents in patients with unresectable stage IIIb, IIIc or IV melanoma amenable to pre and post treatment biopsy. 

Location: Melanoma Institute Australia North Sydney/ RPAH
Trial status: Open
Treatment type: Radiation Therapy
Stage: IV
Intent of treatment:

Title: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomized phase III trial.

Location: RPAH/ Melanoma Institute Australia North Sydney
Trial Status: Open
Treatment type: Chemotherapy
Stage: Advanced
Intent of treatment: Recurrence prevention

Title: A study of the molecular profile of melanoma chemosensitivity and resistance in patients undergoing intravenous limb infusion for metastatic melanoma. 

Location Melanoma Institute Australia North Sydney/ RPAH
Trial Status: Screening phase: Closed/Randomisation Phase: Open
Treatment type: Surgical
Stage: IIA to IIIC
Intent of treatment: Recurrence prevention

Title: Multicenter Selective Lymphadenectomy Trial II (MSLTII): A phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node. 

Location: Melanoma Institute Australia North Sydney/ RPAH
Trial Status: Open
Treatment type: Adjuvant
Stage: IIb, IIc, IIIa (N1a), IIIb (N1a, N2a)
Intent of treatment: Recurrence prevention

Title: A Pilot study of 75 patients to assess the feasibility, safety and toxicity of oral vitamin D over a period of two years. Patients will be randomized to receive either active treatment or placebo. 

Location: Melanoma Institute Australia North Sydney
Trial Status: Open
Treatment type: Oral Chemotherapeutic
Stage: IIIc-IV
Intent: Evaluation of safety and tolerability of study drug. Recurrence Prevention.

Title: An open-label, multicentre expanded access study of Vemurafenib in patients with metastatic melanoma. 

Location: Melanoma Institute Australia North Sydney
Trial status: Open
Treatment type: Oral vs. Intravenous Chemotherapy
Stage: III
Intent of treatment: To compare the clinical efficacy of nilotinib to DTIC, based on progression free survival (PFS), in the treatment of c-Kit mutated melanoma in patients who have not received prior therapy with TKIs.
Target Population: The target population comprises adult patients with unresectable or metastaticc-Kit mutated melanoma who have not received prior therapy with TKIs. Patients must have received no more than 1 (0 or 1) prior systemic anticancer therapies for melanoma before entering the trial. Prior adjuvant therapies administered to the patient will not count towards this number.

Title: The TASIGNA trial (Tasigna efficacy in advanced melanoma): A randomized, phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna® versus dacarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation.

Location: Melanoma Institute Australia North Sydney/ RPAH
Trial status: Open
Stage: III or IV
Treatment type: Oral chemotherapeutic agent
Intent: To assess the objective response rate (ORR; complete response + partial response [CR + PR]) of E7080 in subjects with unresectable stage III or stage IV melanoma not harboring the V600E BRAF mutation and disease progression following firstline standard of care therapy (Cohort 1).

To assess the response rate of E7080 in subjects with unresectable stage III or stage IV melanoma harboring the V600E BRAF mutation and disease progression following BRAF-V600E-targeted therapy (Cohort 2) .

Title: An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma.